{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Palatin Technologies, Inc."},"Symbol":{"label":"Symbol","value":"PTN"},"Address":{"label":"Address","value":"4B CEDAR BROOK DRIVE, CRANBURY, New Jersey, 08512, United States"},"Phone":{"label":"Phone","value":"+1 609 495-2200"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction."},"CompanyUrl":{"label":"Company Url","value":"https://www.palatin.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Carl Spana","title":"President, Chief Executive Officer & Director"},{"name":"John Dodd","title":"Senior Vice President-Preclinical Development"},{"name":"Michael B. Raizman","title":"Chief Medical Officer"},{"name":"Stephen T. Wills","title":"COO, CFO, Secretary, Treasurer & Executive VP"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}